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Abstract
Chemosensitizers can improve the therapeutic index of chemotherapy and overcome treatment 
resistance. Successful translation of chemosensitizers depends on the development of strategies 
that can preferentially deliver chemosensitizers to tumors while avoiding normal tissue. We 
hypothesized that nanoparticle (NP) formulation of chemosensitizers can improve their delivery to 
tumors which can in turn improve their therapeutic index. To demonstrate the proof of principle of 
this approach, we engineered NP formulations of two chemosensitizers, the PI3-kindase inhibitor 
wortmanin (Wtmn) and the PARP inhibitor olaparib. NP Wtmn and NP olaparib were evaluated as 
chemosensitizers using lung cancer cells and breast cancer cells respectively. We found Wtmn to 
be an efficient chemosensitizer in all tested lung-cancer cell lines reducing tumor cell growth 
between 20 and 60% compared to drug alone. NP formulation did not decrease its efficacy in 
vitro. Olaparib showed less consistent chemosensitization as a free drug or in NP formulation. NP 
Wtmn was further evaluated as a chemosensitizer using mouse models of lung cancer. We found 
that NP Wtmn is an effective chemosensitizer and more effective than free Wtmn showing a 32% 
reduction in tumor growth compared to free Wtmn when given with etoposide. Importantly, NP 
Wtmn was able to sensitize the multi-drug resistant H69AR cells to etoposide. Additionally, the 
combination of NP Wtmn and etoposide chemotherapy did not significantly increase toxicity. The 
present study demonstrates the proof of principle of using NP formulation of chemosensitizing 
drugs to improve the therapeutic index of chemotherapy.
Introduction
Chemotherapy is a key component of cancer treatment, and improvement in its therapeutic 
index can directly translate into increase in survival in cancer patients.1 Because of its 
importance, there has been long standing interest in the development of novel approaches to 
improve the therapeutic index of chemotherapy. One strategy is to utilize chemosensitizers, 
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agents that can sensitize tumor cells to chemotherapy, in conjunction with chemotherapy 
regimens. Although some chemosensitizers only enhance chemotherapy effects in cancer 
cells, such as poly (ADP ribose) polymerase (PARP) inhibitors in BRCA deficient cancers, 
other chemosensitizers, such as wortmannin (Wtmn) and 2-morphlin-4-yl-8-
phenylhomen-4-one LY294002, affect both tumor cells as well as cells comprising normal 
tissues.2,3 The sensitization of normal tissues to chemotherapy results in higher treatment 
toxicity which limits the overall therapeutic index of chemotherapy. Thus, few 
chemosensitizers have been translated and evaluated clinically. Successful translation of 
chemosensitizers depends on the development of strategies that can preferentially deliver 
chemosensitizers to tumors while largely avoiding normal tissue. While this has not been 
possible with traditional drug delivery techniques, the development of nanoparticle (NP) 
drug delivery vehicles offers a unique opportunity.
NP therapeutic carriers possess several important characteristics that are well-suited for the 
delivery of chemosensitizers. First, NPs preferentially accumulate in tumors through the 
enhanced permeability and retention (EPR) effect, leading to high intratumoral drug 
concentrations.4,5 A significant increase in therapeutic efficacy can also lead to reductions in 
chemotherapy doses, which in turn would reduce treatment toxicity. Second, NPs have 
reduced permeability to normal vasculature and capillaries, thus leading to lower drug dose 
to normal tissues such as skin, lung, and heart when compared to their small molecule 
counterparts.6 The advantages of NP biodistribution are illustrated in Fig. 1. Third, many NP 
platforms allow slow and controlled drug delivery. Such prolonged release can increase the 
synergistic effects between chemosensitizers and chemotherapy. Because of such unique 
properties we hypothesized that NP delivery of chemosensitizers can improve the 
therapeutic efficacy of chemotherapy without increasing its toxicity.
To explore our hypothesis and to demonstrate the proof of principle of using NP to deliver 
chemosensitizers, we utilized the chemosensitizers olaparib and Wtmn as model drugs. 
Olaparib is a PARP inhibitor and has been shown to sensitize breast cancer cells to 
chemotherapy.7 Wtmn is a potent inhibitor of phosphatidylinositol-4,5-bisphosphate 3-
kinase (PI3 K) and related proteins and is known to sensitize different types of tumor cells to 
treatment.8–10 In this study, we evaluated NP formulations of olaparib and Wtmn as 
chemosensitizers using breast cancer and lung cancer (both small cell and non-small cell 
lung cancer) as tumor models. We compared the therapeutic effects of several 
chemotherapeutics with and without NP chemosensitizers. We also examined the toxicity 
profile of chemotherapy treatment with and without NP Wtmn.
Experimental
Materials
1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-carboxy (polyethylene glycol) 2000 
(DSPE–PEG2000–COOH) and the cross-linkable lipid (1-palmitoyl-2-(10,12-
tricosadiynoyl)-sn-glycero-3-phosphocholine) (PTPC) were obtained from Avanti Polar 
Lipids (Alabaster, AL). Docetaxel (Dtxl), wortmannin (Wtmn), etoposide and gemcitabine 
hydrochloride were purchased from Sigma-Aldrich (St. Louis, MO). Olaparib was 
purchased from Selleckchem (Houston, TX). PLGA (poly(D,L-lactide-co-glycolide)) with a 
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50 : 50 monomer ratio, ester terminated, and viscosity of 0.72–0.92 dl g−1 was purchased 
from Durect Corporation (Pelham, AL). Soybean lecithin consisting of 90–95% 
phosphatidylcholine was obtained from MP Biomedicals (Solon, OH). 200 Proof Ethanol 
(Molecular Biology Grade) and Acetonitrile (HPLC Grade) were purchased from Fisher 
Scientific (Hampton, NH). Dulbeco’s Phosphate Buffer Saline (PBS, 1X) was purchased 
from Gibco by Life Technologies (Carlsbad, CA). H460, H23 and H69AR cell lines were 
purchased from UNC’s Lineberger tissue culture facility.
Formulation and characterization of NP Wtmn and NP olaparib
NP Wtmn and NP olaparib were formulated using a previously described method. Briefly, 
1.0 mg mL−1 of Lecithin and DSPE-PEG-COOH were separately dissolved in 4% ethanol 
and mixed in the molar ratio of 7 : 3 (aqueous solution). The mixture was heated at 55.0 °C 
for about 15 minutes with continuous stirring. Separately, PLGA (10 mg mL−1) and Wtmn 
(1.0 mg mL−1) were dissolved in acetonitrile while olaparib (3.0 mg mL−1) was dissolved in 
acetone. For the preparation of NP Wtmn, 100 μL of PLGA and 100 μL Wtmn solutions 
were mixed together and added dropwise (~1 mL min−1) to the heated aqueous solution. For 
the preparation of NP Olaparib, 100 μL of PLGA and 100 μL of Olaparib solutions were 
mixed in 800 μL of acetonitrile and added dropwise (~1 mL min−1) to the heated aqueous 
solution. Immediately following the addition of the organic solution, the mixture was 
vortexed for 3 minutes. The NPs were allowed to self-assemble for 1 hour with continuous 
stirring followed by washing the solution twice using Amicon Ultra-4 (30 kDa) and 
resuspended in PBS to obtain 1 mg mL−1 of NP concentration.
Drug loading determination
For the determination of percent drug loading, 30 μL NPs samples containing Wtmn or 
olaparib were collected and mixed thoroughly with 120 μL acetonitrile and left overnight to 
disrupt the NPs. Each mixture was subjected to HPLC. Drug concentration was determined 
using standard curves.
In vitro cytotoxicity
In a 96-well plate, 1 × 104 H460, H23 or H69AR cells were plated 24 hours prior to 
treatment with different concentrations of drugs (Etoposide (200 nM), Gemcitabine (2.0 nM) 
or Docetaxel (5.0 nM)). Fresh media was added prior to the drug treatment and incubated 
with the drugs for 24 hours. Chemosensitizer (free Wtmn or NP Wtmn) was added to the 
H460, H23 (5.0 μM) or H69AR (10 μM) cells without washing. Similarly, 5.0 μM of 
olaparib (free or NP) was added to Hs578 T or HCC38 cells following the 24 hour drug 
treatments. The cells were further incubated with the two therapeutics for 6.0 hours, 
bringing the total drug treatment to 30 hours. The cells were subsequently washed with PBS 
and allowed to grow for another 24 hours. Cell viability was analyzed using an MTS [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] 
assay. Briefly, the cells were washed with PBS, followed by the addition of a 120 μL 
mixture of their respective culture medium containing 20% MTS reagent (Promega) and 1% 
phenazine methosulfate (PMS) as the electron coupling reagent (Promega), directly to 
culture wells. H460 cells were incubated for about 30 minutes, H23 cells were incubated for 
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about 45 minutes and H69AR cells were incubated for about 2 hours, after which the plates 
were read at the absorbance value of 490 nm using a 96-well plate reader (BioTek, Synergy 
2). The difference in the timing is reflective of the cellular activity of the different cell lines.
In vivo tumor efficacy
H69AR cells (1 × 106) in 200 μL 1 : 1 serum free RPMI-1640 and matrigel were 
subcutaneously inoculated into right flank of about 8 week-old male nude (nu/nu) mice. Ten 
days after inoculation, the mice were randomly distributed into different groups for 
subsequent treatment. Mice (n = 6–7 per group) were administered either saline, free or NP 
Wtmn (100 μg kg−1), free Etop (20 mg kg−1), or simultaneous injection of free Wtmn and 
Etoposide (100 μg kg−1 Wtmn, 20 mg kg−1 etoposide) or NP Wtmn and Etoposide (100 μg 
kg−1 Wtmn, 20 mg kg−1 etoposide) dosed via a tail vein injections. The tumor volumes were 
measured every two or three days and relative change in tumor volume was calculated using 
the relation V/Vo, where V is the volume calculated and Vo is the initial volume on day 0 
(ten days after the inoculation).
Hepatotoxicity study
Free or NP Wtmn was injected i.v. via tail vein at a dose of 100 μg kg−1 into nude mice (n = 
5 per group) with or without 10 mg kg−1 of Etoposide. Blood was collected from the mice 
24 hours post-injection via submandibular bleed. The blood samples were centrifuged at 
3000 rpm for 10 minutes to separate the plasma. The plasma was then submitted to the 
Animal Clinical Laboratory Core Facility at UNC School of Medicine for analysis of AST 
and ALT levels, which analyzed the samples using an automated chemical analyzer (VT 
350, Ortho Clinical Diagnostics, Rochester, NY). Paired t-test was performed for statistical 
analysis.
Western-Blot
H460 cells were seeded overnight and then treated with chemotherapeutics (etoposide (200 
nM), gemcitabine (2 nM), or docetaxel (5 nM) with saline, free, or NP Wtmn (10 μM) for 
six hours. Cell lysates were then collected in RIPA (25 mM Tris-HCl (pH 7.6), 150 mM 
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) buffer. Protein concentration was 
measured by bicinchonic acid protein assay (Pierce). Primary antibodies were p-AKT 
(Ser473) (Cell Signaling), p-DNA PK (Ser2056) (Abcam), p-mTOR (Ser2448) (Cell 
Signaling), and β-actin (13E5) (Cell Signaling) at dilutions indicated by manufactures. 
Secondary antibodies were α-mouse IgE HRP-linked antibody (Cell Signaling) or α-rabbit 
IgE HRP-linked antibody (Cell Signaling).
Statistical analysis
To statistically compare the cell survival results for the in vitro toxicity studies we 
performed two-way ANOVAs using variables of chemotherapy (saline, docetaxel, 
gemcitabine, or etoposide) and chemosensitizers (saline, free or NP Wtmn). Post-hoc 
analyses were then performed using Tukey’s test to determine significant differences 
between groups when significant interactions were found on ANOVAs. Multiplicity 
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adjusted P values are reported. ANOVA and Tukey’s tests were performed using Prism 
Graphpad software, version 6.05, La Jolla, CA.
For in vivo studies, AUC was calculated for each cohort. We then statistically compared 
tumor growth curves with Wilcoxon rank-sum test (using Van der Waerden normal scores). 
Two-sided P values are reported. These analyses were performed using R statistical 
software, version 3.1.1.
Results and discussion
NP Wtmn is an effective chemosensitizer in vitro
Wtmn- and olaparib-encapsulated PLGA nanoparticles of about 35 nm diameter were 
prepared via nanoprecipitation.11 The lipid-coated PLGA nanoparticles contain 2.0 and 1.3 
wt/wt% of encapsulated Wtmn and olaparib, as determined by quantitative HPLC. Fig. 2 
shows representative TEM images for both NP formulations. Encapsulation efficiency was 
20% for Wtmn and 3% for olaparib.
To evaluate NP Wtmn as a chemosensitizer we utilized lung cancer as a disease model 
because it represents a disease that can greatly benefit from improvements in the efficacy of 
chemotherapy. Three lung cancer cell lines, 2 non-small cell cancer lines (H460 and H23), 
and a multidrug resistant small cell cancer line (H69AR), were chosen for in vitro 
evaluations. NP Wtmn’s efficacy as a chemosensitizer was determined using these tumor 
cells treated with or without chemotherapeutics commonly used in the treatment of lung 
cancer, including etoposide, docetaxel (Dtxl), or gemcitabine. Fig. 3 shows cell viability of 
three different lung cancer cell lines treated with 200 nM etoposide, 2.0 nM gemcitabine or 
5.0 nM docetaxel and free or NP Wtmn (5.0 μM for H460 and H23 and 10 μM for H69AR). 
The addition of Wtmn improved the efficacy of chemotherapeutics. Two-way ANOVA 
showed a main effect of drug, chemosensitizer, and a significant interaction (P < 0.001 for 
all 3 cell lines) between chemotherapy and chemosensitizing agent in both NSCLC lines 
(H460 and H23). As seen in Fig. 3a, H460 cells show about 10–20% reduction in cell 
survival (compared to control) when treated with Wtmn or chemotherapy alone (P < 0.001 
for both). However, the combination of Wtmn and chemotherapy significantly improved 
cytotoxicity producing 60–80% reductions in cell survival. Similar findings were observed 
in H23 cells (Fig. 3b). More importantly, our results showed that NP Wtmn is at least as 
effective as free Wtmn as a chemosensitizer in vitro. In H460 cells and H23 cells, NP Wtmn 
resulted in similar or significantly lower survival rates than free Wtmn in combination with 
all three chemotherapeutics. Wtmn also functioned as a chemosensitizer in the SCLC 
H69AR cells (Fig. 3c). As expected, these cells were chemoresistant and there was no 
significant main effect of chemotherapy on ANOVA. However, they were sensitive to 
Wtmn and the combination of Wtmn and chemotherapy was more effective than 
chemotherapy alone.
Olaparib is a demonstrated chemosensitizer which has been used in clinical trials for patients 
with BRCA mutated breast and ovarian cancers.12–14 We chose breast cancer as a disease 
model to study NP olaparib as a chemosensitizer. Breast cancer cell lines, Hs578 T and 
HCC38, were treated with NP or free olaparib in combination with chemotherapeutics. As 
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seen in Fig. 4a, Hs578 T cells show varied results. Hs578 T cells were sensitive to both 
olaparib and chemotherapy showing 10–30 percent decreases in survival to either (P < 0.001 
for main effects of chemotherapy, sensitizer, and interaction). However, olaparib only 
showed a chemosensitizing effect when given with gemcitabine but not with etoposide or 
docetaxel. In HCC38 cells, free olaparib had significant chemosensitizing effects for each of 
the chemotherapeutics. However, NP olaparib did not improve cytotoxicity to any of the 
chemotherapeutics in these experiments.
NP Wtmn is an effective chemosensitizer in vivo
Based on the in vitro results, we focused our in vivo evaluations on NP Wtmn as a 
chemosensitizer for lung cancer. No in vivo studies were done with breast cancer cells and 
olaparib as NP olaparib did not appear to be a robust chemosensitzier in vitro. We studied 
NP Wtmn’s efficacy as a chemosensitizer using mice bearing H69AR xenografts. As seen in 
Fig. 5, the combination of NP Wtmn and etoposide significantly delayed tumor growth when 
compared to that of free Wtmn and etoposide or etoposide treatment without 
chemosensitization. High-dose etoposide alone was ineffective as a treatment. We also 
confirmed that NP Wtmn was more effective than free Wtmn as a chemosensitizer (P < 
0.03).
NP formulation of Wtmn decreases hepatotoxicity with chemotherapy
Although our previous work has shown that NP delivery of Wtmn minimized its 
hepatoxicity,11 hepatotoxicity remains a potential concern when the drug is given in 
combination with another chemotherapy agent. Hence, we studied the hepatotoxicity profile 
of Wtmn and etoposide in vivo. Results of hepatotoxicity are seen in Fig. 6. As expected, the 
treatment regimen of free Wtmn and etoposide showed high levels of hepatotoxicity (AST: 
302.5 ± 49.1 (normal range: 40–50 U L−1)) which were significantly greater than all other 
treatment cohorts (P < 0.05 for all). In contrast, the addition of NP Wtmn to free etoposide 
did not significantly increase AST or ALT levels compared to etoposide alone.
NP Wtmn prevents activation of DNA repair pathways
To confirm that the molecular mechanism of the Wtmn NP chemosensitization is indeed 
through prevention of DNA repair, we also performed western blot analysis of Wtmn targets 
which are thought to play a key role in DNA repair.15,16 As seen in Fig. 7, H460 cells that 
were treated with chemotherapy had activation of pDNA-PKcs, pAKT and pmTOR (another 
important signaling pathway). The activation of pDNA-PKcs and pAKT were inhibited by 
Wtmn or NP Wtmn. The inhibition from NP Wtmn or free Wtmn was much less for 
pmTOR, suggesting that the main mechanism of chemosensitization is through the 
inhibition of pDNA-PKcs and pAKT.
Discussion
The development of chemosensitizers can improve chemotherapy treatment and overcome 
chemoresistance, a major obstacle in cancer treatment. A key impediment to the clinical 
translation of chemosensitizers has been the lack of targeted delivery of these agents to 
tumors to avoid the sensitization of normal cells to chemotherapy. As discussed above, lipid-
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polymer NPs like those used in these experiments preferentially accumulate in tumors. We 
believe advances in NP drug delivery offer a unique opportunity. Our current study aims to 
demonstrate the proof of principle of using NPs to deliver chemosensitizers.
In this study, we focused on two chemosensitizers: Wtmn and olaparib. Wtmn has broad 
activity against many signaling molecules (including PI3 K, PI3KK, and DNA-PK)17–19 and 
can affect both tumor cells and normal tissue cells. In contrast, olaparib mainly inhibits 
PARP20 and has been shown to have limited systemic toxicity in clinical trials.12–14 By 
engineering and evaluting NP formulations of both of these chemosensitizers, we aimed to 
demonstrate that NP delivery improves chemosensitizers’ efficacy without significantly 
increasing toxicity. In vitro evaluation of NP Wtmn showed that it is an effective 
chemosensitizer and more effective than free Wtmn when combined with etoposide and 
Dtxl. Our previous studies have shown that NP formulations typically are less effective than 
their small molecule counterparts when evaluated in vitro due to the lower intracellular 
uptake.15,16 Therefore, our in vitro results were highly suggestive of NP Wtmn’s potency as 
a chemosensitizer. In this study, we surprisingly observed that NP Wtmn was a more 
effective in vitro chemosensitizer than free Wtmn with docetaxel or etoposide in NSCL 
lines. The mechanism may be explained by the prolonged release of Wtmn from the NPs 
resulting in more effective inhibitors of molecular pathways with longer duration within the 
cell than free Wtmn. It is interesting to note that we did not observe such as effect with 
gemcitabine. The most encouraging result was that NP Wtmn was able to sensitize a highly 
drug resistant cell line H69AR to the effects of chemotherapy.
The results on NP olaparib were mixed. In Hs578 T cells we observed that NP olaparib was 
more effective than free olaparib only when it is combined with gemcitabine. Olaparib did 
not sensitize the tumor cells to etoposide or docetaxel. In HCC38 cells, free olaparib was an 
effective chemosensitizer but NP olaparib was not. Our findings showed that NP 
formulation of olaparib can improve its efficacy as a chemosensitizer in certain selected 
situations but not broadly as Wtmn. There are several reasons for the lack of efficacy of 
olaparib. First, despite the high enthusiasm for PARP inhibition as a strategy to improve 
chemotherapy, preclinical and clinical results have thus far been largely disappointing.12,21 
Therefore, NP delivery may not be able to improve the therapeutic efficacy. Wtmn on the 
other hand is a potent inhibitor of PI3 K and affects a broad range of signaling pathways. 
Thus, it is a better chemosensitizer. As a result, we focused on the in vivo evaluation of NP 
Wtmn as a chemosensitizer.
Using mice bearing H69AR xenografts we demonstrated that NP Wtmn is a potent 
chemosensitizer and is more effective than free Wtmn. As predicted, this drug resistant lung 
cancer cell line was highly resistant to etoposide treatment. However, the addition of NP 
Wtmn sensitized these tumor cells to the effects of etoposide. Since neither Wtmn nor NP 
Wtmn had any effects on the tumor growth, the function of NP Wtmn was entirely as a 
chemosensitizer. Such results confirm that chemosensitizers can overcome treatment 
resistance of tumor cells. Toxicity evaluation showed that the addition of NP Wtmn to 
etoposide did not significantly increase hepatotoxicity, the main toxicity of Wtmn. Such 
results suggest that NP Wtmn has clinical translation potential as a chemosensitizer. Lastly, 
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we showed that the mechanism of chemosensitization of NP Wtmn is likely through 
inhibition of pDNA-PKcs and pAKT pathways.
Conclusions
In conclusion, we have shown that NP formulation of chemosensitizers can improve their 
therapeutic efficacy. Moreover, NP chemosensitizers can be co-administered with 
chemotherapy without increasing toxicity. By improving the therapeutic index of systemic 
chemotherapy it is possible that NP delivery of chemosensitizers could lead to improved 
clinical outcomes. Future studies could investigate the potential to co-deliver 
chemosensitizing agents with chemotherapeutics such as gemcitabine or adding NP 
chemosensitizers with combination chemotherapy regimens. Our results provide proof of 
principle for NP delivery of chemosensitizers with systemic chemotherapy and provide a 
basis for further study.
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Lung cancer treatment with small molecule chemosensitizers (A) or NP chemosensitizers 
(B). With small molecule chemosensitizers, there is more normal lung that receives both 
chemotherapy and chemosensitizer. In contrast, NP chemosensitizers preferrentially 
accumulate in tumors, which can improve chemosensitizer concentration in tumor while 
reducing dose to normal lung.
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Representative TEM images of NP Wtm (A) and NP olaparib (B). The black scale bar in the 
left lower corner of each image denotes a distance of 100 nm.
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Effects of NP formulation of Wtmn on in vitro chemosensitivity in human lung cancer cell 
lines. Survival of H460 (A), H23 (B), and H69AR (C) lung cancer cell lines treated with 
gemcitabine, docetaxel, or etoposide following treatment with saline, (black bars), free (light 
grey bars) or NP Wtmn (dark grey bars) was determined using clonogenic survival assays. * 
indicates significantly less survival (P < 0.05) than control. ** indicates significantly less 
surival (P < 0.05) than both groups. N = 6–12 per treatment group.
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Effects of NP formulation of olaparib on in vitro chemosensitivity in human breast cancer 
cell lines. Survival of Hs578 T (A) and HCC 38 (B) breast cancer cell lines treated with 
gemcitabine, docetaxel, or etoposide following treatment with saline (black bars), free (light 
grey bars) or NP olaparib (dark grey bars) was determined using clonogenic survival assays. 
* indicates significantly less survival (P < 0.05) than control. ** indicates significantly less 
surival (P < 0.05) than both groups. N = 6–12 per treatment group.
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In vivo efficacy of NP Wtmn. Mice were innoculated with flank tumors of H69AR human 
SCLC cells. They were then treated with saline (black circles) or etoposide (open triangles). 
To evaluate free Wtmn as a chemosensitizer mice were treated with free Wtmn (closed blue 
squares) or free Wtmn + etoposide (open blue squares). To evaluate NP Wtmn as a 
chemosensitizer mice were treated with NP Wtmn (closed red circles) or NP Wtmn + 
etoposide (open red circles). * indicates significantly different AUC from all other treatment 
groups. N = 6–7 per treatment group.
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NP formulation of Wtmn reduces hepatotoxicity. Mice were injected with 10 mg kg−1 
etoposide, 100 μg kg−1 free or NP Wtmn, or both etoposide and Wtmn. Blood was then 
collected 24 hours later and AST (A) and ALT (B) levels were analysed. * indicates 
significantly greater than all other treatment groups. N = 4 per treatment group.
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NP Wtmn inhibits DNA repair. Western blot analyses were used to measure the activation 
(phosphorylation) of DNA repair proteins DNA-PK, AKT, and mTOR. Activation was 
inhibited by both free and NP Wtmn.
Caster et al. Page 15
Nanoscale. Author manuscript; available in PMC 2016 February 14.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
